BHC

AI Memo

Bausch Health Companies

As of 2026-10-24/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-24 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

October 28 third-quarter results • 2026-10-28

Base target: $7 / p=50% prob

Biggest risk

A slowdown in Xifaxan or weaker cash conversion could undermine the raised outlook and limit debt reduction. Q3 results have not yet been reported, so neither outcome is established.

Invalidation

Break below $5 or thesis failure.

What would change my mind?

Q2 consolidated revenue rose 13% year over year to $2.85 billion, with 11% organic growth; the company raised its 2026 outlook. Continued Salix growth and cash generation would support an upside case. [#SEC-8K-2026-07-29]

Research note

Recommendation

—

Confidence

medium

As of

2026-10-24

Base target

p=50%

Bull target

p=25%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Xifaxan growth durability
Cash conversion and debt reduction
Q2 consolidated revenue rose 13% year over year to $2.85 billion, with 11% organic growth; the company raised its 2026 outlook.

BearKey bullets

Cash conversion and net-debt reduction may prove uneven; Q2 alone does not establish a durable trend.
[#SEC-8K-2026-07-29]
No current analyst revisions, verified recent-news tone or post-Q3 market reaction are available.

WatchKey bullets

October 28 third-quarter results

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $7 (p=50%)

Target spread vs base: +29% / -29%

Scenario probabilities

Bull Target: $9 (p=25%)Base Target: $7 (p=50%)Bear Target: $5 (p=25%)

Commentary

The Q2 company release was positive, but the deterministic directional prior is neutral and Q3 remains ahead. Recent-news, social, options, short-interest and employee-sentiment measurements are unavailable; the zero fields are missing-data placeholders, not neutral readings. No Q3 price reaction or current analyst revisions can yet be assessed. The October 28 event warrants monitoring rather than a stronger directional call.

As of 2026-10-24 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

A slowdown in Xifaxan or weaker cash conversion could undermine the raised outlook and limit debt reduction. Q3 results have not yet been reported, so neither outcome is established.

Drivers

Scannable catalysts and supporting factors

Xifaxan growth durability
Cash conversion and debt reduction

Scenarios

Bull Target (Scenario probability)

$9 / p=25% prob

Base Target (Scenario probability)

$7 / p=50% prob

Bear Target (Scenario probability)

$5 / p=25% prob

Analysis 2026-10-24 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-10-28
October 28 third-quarter results
Bausch Health says it will report Q3 results after market close on October 28. The key test is whether results sustain the higher 2026 revenue, adjusted EBITDA and adjusted operating-cash-flow guidance announced with Q2. No Q3 surprise or guidance revision is yet known. [#PR-EARNINGS-2026-10-06] [#8-K-2026-07-29] [#SEC-8K-2026-07-29]
Prob 95.00% • Move 0.00% • Priced-in 75.00%

Short-term Catalysts

Next few weeks

Xifaxan growth durability
2026-10-28
The Q2 company exhibit attributed Salix growth primarily to Xifaxan, whose revenue rose 26% year over year. Q3 results can test whether that strength persisted; October 28 is an observation date, not a separately announced product milestone. [#SEC-8K-2026-07-29]
Prob 60% • Move 5% • Priced-in 60%

Long-term Catalysts

Months to a year

Cash conversion and debt reduction
2026-12-31
Bausch Health excluding Bausch + Lomb reported $517 million of Q2 operating cash flow, while management highlighted net-debt reduction and raised its 2026 adjusted operating-cash-flow guidance. Sustained conversion could improve financial flexibility; the year-end date is a monitoring horizon, not an announced debt milestone. [#SEC-8K-2026-07-29]
Prob 55% • Move 8% • Priced-in 45%

Risks

Cash conversion and net-debt reduction may prove uneven; Q2 alone does not establish a durable trend. [#SEC-8K-2026-07-29]
No current analyst revisions, verified recent-news tone or post-Q3 market reaction are available.
Q3 results or guidance could disappoint after Q2's raised 2026 outlook. [#SEC-8K-2026-07-29]
Xifaxan-led Salix growth may not persist at its Q2 pace. [#SEC-8K-2026-07-29]

Peers

Symbol	Summary
COO	Cooper's December 2025 SEC filing names Bausch Health among CooperVision's contact-lens competitors. COO is only a product-specific Bausch + Lomb reference, not a whole-company valuation peer; the supplied relationship status is uncertain and exposure is undisclosed. The two observations derive from the same filing, not independent evidence: https://www.sec.gov/Archives/edgar/data/711404/000162828025055615/coo-20251031.htm [#REL-2aae3ff8-1562-4f6b-b99c-9459d8394328] [#REL-1979e22b-2163-44ae-b914-482eb9a82b0c]
GILD	A broad commercial-pharma reference from the supplied candidates, but much larger and not directly comparable on product mix or capital structure.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-24

Loading AI feed…

Symbol

Summary

COO

Cooper's December 2025 SEC filing names Bausch Health among CooperVision's contact-lens competitors. COO is only a product-specific Bausch + Lomb reference, not a whole-company valuation peer; the supplied relationship status is uncertain and exposure is undisclosed. The two observations derive from the same filing, not independent evidence: https://www.sec.gov/Archives/edgar/data/711404/000162828025055615/coo-20251031.htm [#REL-2aae3ff8-1562-4f6b-b99c-9459d8394328] [#REL-1979e22b-2163-44ae-b914-482eb9a82b0c]

GILD

A broad commercial-pharma reference from the supplied candidates, but much larger and not directly comparable on product mix or capital structure.